COMMUNIQUÉS West-GlobeNewswire

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
16/06/2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, [...]
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
16/06/2026
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 [...]
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
16/06/2026
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary [...]
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
16/06/2026
Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026 ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard [...]
Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water
16/06/2026
Follows U.S. EPA's April 2026 decision to include microplastics as a priority contaminant group under the Safe Drinking Water Act's draft Contaminant Candidate List Company underscores relevance of advanced filtration [...]
Transactions in connection with share buy-back program
16/06/2026
Company announcement no. 21 - 26 16 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
16/06/2026
Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants in second dose [...]
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
16/06/2026
IND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing [...]
VitalHub Announces Deployments of Referral Management Solutions
16/06/2026
TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that Novari Health, a VitalHub company, has executed agreements to implement wait list and [...]
Weston Family Foundation invests an additional $37 million to safeguard one of Canada’s most ecologically valuable and threatened ecosystems
16/06/2026
The conservation initiative brings together Indigenous communities, ranchers, and conservation organizations to protect Canada’s critical prairie grasslands TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- The Weston Family [...]
Breckenridge Brewery Launches a Colorado-Wide Soccer Celebration with Fan-First Activations
16/06/2026
With watch parties, foosball competitions, trivia, limited-release beer, and match-day specials, Breckenridge Brewery is creating tournament moments for fans across Colorado all summer long BRECKENRIDGE, Colo., June 16 [...]
My Derma Dream MyoGlow Examined 2026 - Why Is the MyoGlow Arm Device Getting So Much Attention Across the United States?
16/06/2026
Miami, Florida, June 16, 2026 (GLOBE NEWSWIRE) -- There is a quiet conversation happening in fitting rooms, group texts, and medical offices all over the country that rarely surfaces publicly. It is about arms. More [...]
nCAP Medical Announces Publication of Positive RCT Results Demonstrating NeuroCuple® Provides Meaningful, Opioid-Sparing Pain Relief Immediately Following Total Knee Arthroplasty
16/06/2026
The study, published in the Journal of Arthroplasty, highlighted that the Company’s NeuroCuple® Nanotechnology Device achieved statistically significant reduction in opioid use, pain, and hospital length of stay, as [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/06/2026
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
King Faisal Specialist Hospital Showcases Applied AI Ecosystem in Radiology at HLTH Europe 2026
16/06/2026
AMSTERDAM, June 16, 2026 (GLOBE NEWSWIRE) -- Professor Ahmad AbuSalah, PhD, Director of the Digital Innovation Hub at King Faisal Specialist Hospital & Research Centre (KFSH), is presenting the hospital's model for [...]
À l’occasion du congrès HLTH Europe 2026, le King Faisal Specialist Hospital présente son écosystème d’IA appliquée en radiologie
16/06/2026
AMSTERDAM, 16 juin 2026 (GLOBE NEWSWIRE) -- Le professeur Ahmad AbuSalah, titulaire d’un doctorat, directeur du Digital Innovation Hub au King Faisal Specialist Hospital & Research Centre (KFSH), présente le modèle [...]
Aplagon Announces EUR 5 Million Financing to Broaden Phase 2 Trials of its APAC Therapy in Thrombo-Inflammatory Diseases
16/06/2026
Financing Supports Phase 2 Clinical Trial for Arteriovenous Fistula Maturation Failure in End Stage Kidney Disease HELSINKI, June 16, 2026 (GLOBE NEWSWIRE) -- Aplagon , a clinical-stage biotechnology company developing [...]
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
16/06/2026
REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
16/06/2026
REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar [...]

Pages